Exelixis EXEL
NASDAQ EXEL
$59.02 -0.11 (-0.19%)
As of: Sep 4, 2026 · 3:59 PM EDT

Exelixis (EXEL) Revenue Growth (1y) (2011 - 2026)

Analysis

Exelixis (EXEL) Revenue Growth (1y) (2011 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 12.45%
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 16.73%
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 59.71%
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 2.11%
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 29.63%
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 66.86%
8 Royalty Pharma 28.45 Bn 27.61 Bn - 16.50%
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 296.11%
10 Exelixis 14.81 Bn 13.97 Bn 608.03 Mn 10.63%
Historic Data

Historic Data

Download Data
DateValue
Jul 3, 2026 10.63%
Apr 3, 2026 9.97%
Jan 2, 2026 5.63%
Oct 3, 2025 10.79%
Jul 4, 2025 -10.82%
Apr 4, 2025 30.62%
Jan 3, 2025 18.16%
Sep 27, 2024 14.33%
Jun 28, 2024 35.61%
Mar 29, 2024 4.02%
Dec 29, 2023 13.15%
Sep 29, 2023 14.62%
Jun 30, 2023 12.02%
Mar 31, 2023 14.83%
Sep 30, 2022 25.37%
Jul 1, 2022 8.89%
Apr 1, 2022 31.73%
Oct 1, 2021 42.12%
Jul 2, 2021 48.44%
Apr 2, 2021 19.09%